GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Other Income (Expense)

Zenith Capital (Zenith Capital) Other Income (Expense) : $ Mil (TTM As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Other Income (Expense)?

Zenith Capital's other income expense for the Zenith Capital's pretax income for the three months ended in . 20 was $0.00 Mil.

Zenith Capital Other Income (Expense) Historical Data

The historical data trend for Zenith Capital's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Other Income (Expense) Chart

Zenith Capital Annual Data
Trend
Other Income (Expense)

Zenith Capital Quarterly Data
Other Income (Expense)

Zenith Capital Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Zenith Capital  (OTCPK:ZHCLF) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Zenith Capital (Zenith Capital) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Other Income (Expense)
Comparable Companies
CBIO VINC AVTX UNCY TCRT ENTX SKYE PMCB HEPA ELEV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1
Website
Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines